Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HK2 | P52789 | 5/20 | 0.45 |
| ▸ | HK1 | P19367 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.37 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | PYGB | P11216 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6674579 | 1.00 | KDM4E (0.48) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL28461019 | 1.00 | KDM4E (0.48) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL1085802 | 0.86 | KDM4E (0.46) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL24651209 | 0.78 | ALDH1A1 (0.40) | MAPK1CA1CA2CA9LGALS8 | |
| SCHEMBL28081071 | 0.77 | KDM4E (0.44) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL10344862 | 0.76 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL10325486 | 0.76 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL28919637 | 0.76 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL10325207 | 0.76 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL16580127 | 0.75 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120158449-A | Selenium-modified double-stranded oligonucleotides, conjugates, compositions and uses thereof | 北京炫景瑞医药科技有限公司 | 2025-06-17 | — | — | CN | claimed |
| EP-4511485-A1 | COMPOSITIONS AND METHODS FOR ENHANCING AAV THERAPY AND DECREASING TROPISM OF AAV TO THE LIVER | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | claimed |
| CN-118834257-A | Modified double-stranded oligonucleotide conjugates, compositions and uses thereof | 北京炫景瑞医药科技有限公司 | 2024-10-25 | — | — | CN | claimed |
| CN-117186172-A | Conjugate group, conjugate, preparation method and application thereof | 上海鼎新基因科技有限公司 | 2023-12-08 | — | — | CN | claimed |
| US-20230392154-A1 | TARGETED NUCLEIC ACID THERAPY FOR HEPATITIS B | SIRNAOMICS, INC. | 2023-12-07 | — | — | US | claimed |
| WO-2023205606-A1 | COMPOSITIONS AND METHODS FOR ENHANCING AAV THERAPY AND DECREASING TROPISM OF AAV TO THE LIVER | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | claimed |
| EP-4077677-A1 | RNA NANOPARTICLE FOR LIVER CANCER TREATMENT | Ohio State Innovation Foundation (US) | 2022-10-26 | — | — | EP | claimed |
| CN-115244064-A | Targeted delivery of therapeutic molecules | 圣诺制药公司 | 2022-10-25 | — | — | CN | claimed |
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4720291-A1 | METHODS FOR DIRECTING LIPID NANOPARTICLES IN VIVO | Vertex Pharmaceuticals Incorporated (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12582668-B2 | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | Arrowhead Pharmaceuticals, Inc. (US) | 2026-03-24 | — | — | US | disclosed |
| WO-2025238236-A1 | POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL | TARGIMMUNE THERAPEUTICS AG (CH) | 2025-11-20 | — | — | WO | disclosed |
| EP-4622652-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER AND METABOLIC DISEASE | Pretzel Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4615511-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TargImmune Therapeutics AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| CN-105164261-B | Compounds and methods for enhanced cellular uptake | 莱古路斯治疗法股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022043531-A1 | 7'-SUBSTITUTED 2'-O-4'-C-ETHYLENE-BRIDGED NUCLEIC ACID (ENA) MONOMERS AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-03 | — | — | WO | disclosed |
| US-20210214726-A1 | Peptide Docking Vehicle for Targeted Nucleic Acid Delivery | SIRNAOMICS, INC. | 2021-07-15 | — | — | US | disclosed |
| WO-2021113851-A2 | PEPTIDE DOCKING VEHICLE FOR TARGETED NUCLEIC ACID DELIVERY | SIRNAOMICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-10806750-B2 | RNAi therapy for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190022123-A1 | RNAi Therapy for Hepatitis B Virus Infection | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806750-B2 | RNAi therapy for hepatitis B virus infection | HAVCR2, NR1H4, SRRT | KDM4E 3124/4885LMNA 2737/4885CYP2D6 3679/4885 |
| US-12582668-B2 | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | UPF1, RNGTT, SERPINA2 | KDM4E 4470/4885LMNA 580/4885CYP2D6 3581/4885 |
| US-20190022123-A1 | RNAi Therapy for Hepatitis B Virus Infection | HAVCR2, NR1H4, SRRT | KDM4E 3124/4885LMNA 2737/4885CYP2D6 3679/4885 |
| US-20230392154-A1 | TARGETED NUCLEIC ACID THERAPY FOR HEPATITIS B | HAVCR2, POLRMT, FABP1 | KDM4E 4314/4885LMNA 1168/4885CYP2D6 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.